Circio Holding ASA

Regulatory Filings • Jan 12, 2026

Circio invites to live webcast on 15 January 2026 to provide information about the upcoming rights issue

Circio invites to live webcast on 15 January 2026 to provide information about the upcoming rights issue

* Circio is intending to raise up to NOK 50 million in a rights issue, with

strong support from several of its main shareholders

* Existing and new shareholders can subscribe in the rights issue during the

period 15-29 January 2026

* In the webcast, CEO Dr. Erik D Wiklund will provide an overview of the

transaction structure and timelines, as well as a general corporate update

Oslo, Norway, 12 January 2026 -- Circio Holding ASA (OSE: CRNA), a

biotechnology company developing novel circular RNA expression technology for

gene and cell therapy, invites to a live webcast at 10:00am CET on Thursday 15

January 2026.

On 8 December 2025, Circio announced a proposed rights issue of up NOK 50

million

(https://www.circio.com/en/circio-announces-88-underwritten-and-presubscribed-nok-50-million-rights-issue-with-strong-support-from-existing-shareholders/)

with strong support from several of its main shareholders. The rights issue is

88% covered by pre-subscriptions and guarantee commitments. On 12 January

2026, the extraordinary general meeting of Circio approved the proposed

transaction, and investors can subscribe in the rights issue during the period

15-29 January 2026.

In the webcast, CEO Dr. Erik D Wiklund will provide information and timelines

for the rights issue, as well as a general corporate update. The webcast will

be held in Norwegian. Questions can be submitted in advance by email to:

erik.wiklund@circio.com or directly in the live webcast.

Time: 10:00 CET on Thursday 15 January 2026

Click here to access Teams webcast

(https://teams.microsoft.com/meet/36433317780132?p=o6uASbzdro4UY7jCzz)

Meeting ID: 364 333 177 801 32

Passcode: PM96YW9U

A recording of the webcast will be made available on the Circio webpage

(http://www.circio.com/)

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683 34 3811

Email: lubor.gaal@circio.com

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 40-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through cost-efficient external academic and industry

collaborations. TG01 targets RAS-mutated cancers and is being tested in two

clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine

adjuvanted by STIMULON QS-21 licensed from Agenus Inc.